R K Khanna1, R Hage2, A Lecler3, T Sene4, C Vignal-Clermont2, G Clavel-Refregiers4. 1. Department of ophthalmology, Fondation Adolphe-de-Rothschild hospital, 29, rue Manin, 75019 Paris, France. Electronic address: raoul.khanna@univ-tours.fr. 2. Department of ophthalmology, Fondation Adolphe-de-Rothschild hospital, 29, rue Manin, 75019 Paris, France. 3. Department of neuroradiology, Fondation Adolphe-de-Rothschild hospital, Paris, France. 4. Department of internal medicine, Fondation Adolphe-de-Rothschild hospital, Paris, France.
Abstract
PURPOSE: To report the case of a patient with arteritic anterior ischemic optic neuropathy (AAION) with a history of glucocorticoids (GC) hypersensitivity treated with monthly intravenous tocilizumab (IV TCZ) and short course of GC. CASE REPORT: A 71-year-old Caucasian patient presented with AAION related to giant cell arteritis (GCA) confirmed by temporal artery biopsy. Past medical history was significant for GC hypersensitivity proven by allergy evaluation and the patient was managed with IV TCZ and very short-course GC. CONCLUSION: TCZ therapy with very short-course GC could be effective in GCA with ophthalmic involvement as a first-line strategy. Clinical trials are needed for thorough evaluation of the efficiency of TCZ as a first-line treatment to induce and maintain remission in patients with GCA and ocular involvement.
PURPOSE: To report the case of a patient with arteritic anterior ischemic optic neuropathy (AAION) with a history of glucocorticoids (GC) hypersensitivity treated with monthly intravenous tocilizumab (IV TCZ) and short course of GC. CASE REPORT: A 71-year-old Caucasian patient presented with AAION related to giant cell arteritis (GCA) confirmed by temporal artery biopsy. Past medical history was significant for GC hypersensitivity proven by allergy evaluation and the patient was managed with IV TCZ and very short-course GC. CONCLUSION:TCZ therapy with very short-course GC could be effective in GCA with ophthalmic involvement as a first-line strategy. Clinical trials are needed for thorough evaluation of the efficiency of TCZ as a first-line treatment to induce and maintain remission in patients with GCA and ocular involvement.
Authors: Javier Loricera; Santos Castañeda; Clara Moriano; Javier Narváez; Vicente Aldasoro; Olga Maiz; Rafael Melero; Ignacio Villa; Paloma Vela; Susana Romero-Yuste; José L Callejas; Eugenio de Miguel; Eva Galíndez-Agirregoikoa; Francisca Sivera; Jesús C Fernández-López; Carles Galisteo; Iván Ferraz-Amaro; Julio Sánchez-Martín; Lara Sánchez-Bilbao; Mónica Calderón-Goercke; Alfonso Casado; José L Hernández; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2022-07-22 Impact factor: 3.625